Health Canada approved a generic version of the semaglutide injection, known by the brand name Ozempic, on April 29, 2026 [1].
This regulatory move marks a significant shift in the availability of GLP-1 receptor agonists. While the drug is widely recognized for its impact on weight loss, the current approval is limited specifically to the treatment of diabetes [3].
Canada is the first G7 nation to allow a generic version of a semaglutide injection [3]. This development could potentially lower the cost of treatment for patients managing type 2 diabetes, provided the generic enters the market at a competitive price point.
Despite the general approval of the drug, medical specialists warn against misconceptions regarding its intended use. Dr. Sue Pedersen, a specialist in metabolism and obesity medicine, said that the generic version is not yet formally approved for weight management [1].
"The generic version hasn't been formally approved for weight management yet," Pedersen said [1].
Under current Health Canada regulations, a separate formal approval process is required for a drug to be indicated for weight-management use [3]. The generic semaglutide must undergo this additional scrutiny before it can be legally marketed for obesity treatment.
Patients seeking weight loss may find the news confusing, as some reports suggest the generic approval could help Canadians lose weight [1]. However, the formal regulatory status remains restricted to diabetes indications [1].
“Canada is the first G7 nation to allow a generic version of a semaglutide injection.”
The approval of generic semaglutide creates a pathway for more affordable diabetes care in Canada and sets a regulatory precedent among G7 nations. However, the gap between diabetes approval and weight-management approval may lead to increased off-label prescribing or patient confusion until Health Canada decides on the latter indication.
